Anitocabtagene autoleucel vs BCMA CAR-NK (Shenzhen Pregene Biopharma)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Anitocabtagene autoleucel
Developed by Gilead Sciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05396885 (registry estimate)
No aligned efficacy figure on record for this race.
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Developed by Shenzhen Pregene Biopharma Co., Ltd.
NCT05652530 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anitocabtagene autoleucel | BCMA CAR-NK (Shenzhen Pregene Biopharma) |
|---|---|---|
| PFS, median | —Trial running · NCT06413498 | —Not reported |
| OS, median | —Trial running · NCT06413498 | —Not reported |
| ORR | —Trial running · NCT06413498 | —Not reported |
| VGPR or better | —Trial running · NCT06413498 | —Not reported |
| MRD negativity | —Trial running · NCT06413498 | —Not reported |
PFS, median
- Anitocabtagene autoleucel
- —Trial running · NCT06413498
- BCMA CAR-NK (Shenzhen Pregene Biopharma)
- —Not reported
OS, median
- Anitocabtagene autoleucel
- —Trial running · NCT06413498
- BCMA CAR-NK (Shenzhen Pregene Biopharma)
- —Not reported
ORR
- Anitocabtagene autoleucel
- —Trial running · NCT06413498
- BCMA CAR-NK (Shenzhen Pregene Biopharma)
- —Not reported
VGPR or better
- Anitocabtagene autoleucel
- —Trial running · NCT06413498
- BCMA CAR-NK (Shenzhen Pregene Biopharma)
- —Not reported
MRD negativity
- Anitocabtagene autoleucel
- —Trial running · NCT06413498
- BCMA CAR-NK (Shenzhen Pregene Biopharma)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Anitocabtagene autoleucel: no structured comparison results are available for Multiple Myeloma.
BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anitocabtagene autoleucel's landscape · BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape